Focused On-demand Library for Transportin-3

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q9Y5L0

UPID:

TNPO3_HUMAN

Alternative names:

Importin-12; Transportin-SR

Alternative UPACC:

Q9Y5L0; A4D1K9; C9IZM0; Q6NUM1; Q96G71; Q96GU9; Q9Y3R2

Background:

Transportin-3, also known as Importin-12 and Transportin-SR, plays a crucial role in cellular function by transporting target proteins into the nucleus. It specifically facilitates the nuclear import of splicing factor serine/arginine (SR) proteins and is essential for the proper regulation of gene expression. Additionally, Transportin-3 is involved in the nuclear import of the pre-integration complex (PIC) of HIV-1, highlighting its role in viral infection processes.

Therapeutic significance:

The association of Transportin-3 with limb-girdle muscular dystrophy, autosomal dominant 2, underscores its therapeutic significance. This connection to a specific muscular dystrophy suggests that targeting Transportin-3 could lead to innovative treatments for this debilitating condition. Understanding the role of Transportin-3 could open doors to potential therapeutic strategies.